Verträglichkeit und immunogenität einer 3-komponenten-azellulären pertussis-vakzine (DTPa) im vergleich zur klassischen DTPg-Vakzine: Ergebnis einer doppelblinden randomisierten multizenterstudie

Monatsschrift fur Kinderheilkunde

Volumn 144, Issue 2, 1996, Pages 159-166

  Wiersbitzky, S ^a   Bock, H L ^b   Bruns, R ^a   Clemens, R ^b   Graul, G ^c   Koditz H ^d   Padelt, H ^e   Schneeweiss B ^a,f   Meister, W ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b SmithKline Beecham Pharma   (Germany)

^c Kinderarztpraxis   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e HELIOS KLINIKUM BERLIN BUCH   (Germany)

^f Krankenhauses im Friedrichshain   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXOID; PERTUSSIS VACCINE; TETANUS TOXOID;

ADVERSE DRUG REACTION; ANTIBODY DETECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INCIDENCE; INFANT; MULTICENTER STUDY; NORMAL HUMAN; PERTUSSIS; RANDOMIZED CONTROLLED TRIAL; RASH; VACCINATION; VOMITING;

EID: 0029980755     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ad hoc group for the study of pertussis vaccines (1988) Placebocontrolled trial of two acellular pertussis vaccines in Sweden: Protective efficacy and adverse events. Lancet I: 955-960
2. Anderson E, Belshe R, Bartram J, Gurwith M, Hung P, Levner M, Vernon S (1987) Clinical and serologic responses to acellular pertussis vaccine in infants and young children. Am J Dis Child 141: 949-953
3. Aoyama T, Hagiwara S, Murase Y, Kato T, Iwata T (1986) Adverse reactions and antibody responses to acellular pertussis vaccine. J Pediatr 109: 925-930
4. Aoyama T, Iwata T, Iwai H, Murase Y, Saito T, Akamatsu T (1993) Efficacy of acellular pertussis vaccine in young infants. J Infect Dis 167: 483-486
5. Baraff L, Cody C, Cherry J (1984) DTP-associated reactions: An analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics 73: 31-36
6. Bernstein D, Smith V, Schiff G, Rathfon H, Boscia J (1993) Comparison of acellular pertussis vaccine with whole cell vaccine as a booster in children 15 to 18 months and 4 to 6 years of age. Pediatr Infect Dis J 12: 131-135
7. Bernstein H, Rothstein E, Pennridge Pediatric Associates, Reisinger K, Blatter M, Arbeter A, Fontana M, Jacobs J, Long S, Rathfon H, Crayne O, Krause D (1994) Comparison of a three-component acelluiar pertussis vaccine with a whole-cell pertussis vaccine in 15-through 20-month-old infants. Pediatrics 93: 656-659
8. Blennow M, Granström M, Olin P, Tiru M, Jäatmaa E, Askelöf P, Sato Y (1986) Preliminary data from a clinical trial (phase 2) of an acellular pertussis vaccine. Dev Biol Stand 65: 185-190
9. Camargo ME (1984) Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol 20: 772-774
10. Edwards K, Bradley R, Decker M, Palmer P, Savage J. Taylor J, Dupont W, Hager C, Wright P (1989) Evaluation of a new highly purified pertussis vaccine in infants and children. J Infect Dis 160: 832-837
11. England J, Decker M, Edwards K, Pichichero M, Steinhoff M, Anderson E (1994) Accellular and whole-cell pertussis vaccines as booster doses: A multicenter study. Pediatrics 93: 37-43
12. Finger H, Wirsing von König CH (1992) Epidemiologic des Keuchhustens. Gesundheitswesen 54: 541-545
13. Kanra G, Ceyhan M, Vandevoorde D, Bogaerts H (1993) Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69kDa outer membrane protein as a booster in children. Eur J Pediatr 152: 478-483
14. Mebel S, Dittmann S (1988) The impact of a long standing pertussis immunization program. FEMS Symposium on pertussis, Berlin DDR, pp 332-432
15. Miller E (1992) Pertussis in the UK. Commun Dis Rep CDR Rev 2: 152-154
16. Melville-Smith M, Seagroatt V, Watkins J (1983) A comparison on enzyme linked immunosorbent assay (ELISA) with the toxin neutralisation test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 11: 137-144
17. Melville-Smith M. Balfour A (1988) Estimation of corynebacterium diphtheria antitoxin in human sera: A comparison of an enzyme-linked immunosorbent assay with the toxin neutralisation test. J Med Microbiol 25: 279-283
18. Mortimer E, Kimura M, Cherry J, KunoSakai H, Stout M, Dekker C Hayashi R, Miyamoto Y, Scott J, Aoyama T, Isomura S, Iwata T, Kamiya H, Kato T, Nova J, Suzuki E, Takeuchi Y, Yamaoka H (1990) Protective efficacy of the takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanase children. Am J Dis Child 144: 899-904
19. Pichichero M, Badgett J, Rodgers G, McLinn S, Trevino-Scatterday B, Nelson J (1987) Acellular pertussis vaccine: Immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children. Pediatr Infect Dis J 6: 352-363
20. Onorato IM, Wassilak SGF (1987) Laboratory diagnosis of pertussis: The state of the art. Pediatr Infect Dis J 6: 145-151
21. Romanus V, Jonsell R, Bergquist SO (1987) Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 6: 364-371
22. Schmitt HJ, Wirsing von König C, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, Gahr M, Schult R, Folkens JU, Ruh W, Clemens R (1995) Protective efficacy of an acellular pertussis DTaP vaccine following household exposure to pertussis. Abstract J73, IC-AAC, Orlando. USA 1994
23. Schmitz M, Wassilak SGF, Schulte-Wissermann H, Wirsing von König CH (1994) Schätzung zur Pertussis-Inzidenz am linken Niederrhein. Monatsschr Kinderheilkd 142: 41-44
24. Sitzmann F (1994) Pertussis und azelluläre Pertussisimpfstoffe. Kinderarzt 25: 50-56
25. Stehr K, Heininger U (1991) Stand der Keuchhustenschutzimpfung. Padiatr Prax 42: 391-402
26. Storsaeter J, Olin P (1992) Relative efficacy of two accellular pertussis vaccines during three years of passive surveillance. Vaccine 10: 142-144
27. Stück B (1990) Zur Impfung gegen Pertussis. Gelbe Hefte 30: 160-171
28. Thomas MG, Redhead K, Lambert H (1989) Human serum antibody responses to Bordetella pertussis infection and vaccination. J Infect Dis 159: 211-218
29. Vanura H, Just M, Ambrosch F, Berger RM, Bogaerts H, Wynen J, Vandevoorde D, Wiedermann G (1994) Study of pertussis vaccines in infants: Comparison of response to acellular pertussis DTP vaccines containing 25 g of FHA and either 25 or 8 g of PT with response to wholecell pertussis DTP vaccine. Vaccine 12: 210-214
30. Wirsing von Konig CH (1993) Keuchhusten: Mikrobiologie, Epidemiologie, Prophylaxe. Gelbe Hefte 33: 80-86
31. Wirsing von König CH, Finger H (1994) Role of pertussis toxin in causing symptoms of Bordetella parapertussis infection. Eur J Clin Microbiol Infect Dis 13: 455-458